Department of Molecular and Cell Biology, Faculty of Basic Sciences, University of Tehran, Tehran, Iran.
Tuberculosis and Lung Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
J Adv Res. 2021 Jul;31:49-60. doi: 10.1016/j.jare.2020.12.013. Epub 2021 Jan 5.
The recent ongoing outbreak of coronavirus disease 2019 (COVID-19), still is an unsolved problem with a growing rate of infected cases and mortality worldwide. The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is targeting the angiotensin-converting enzyme 2 (ACE2) receptor and mostly causes a respiratory illness. Although acquired and resistance immunity is one of the most important aspects of alleviating the trend of the current pandemic; however, there is still a big gap of knowledge regarding the infection process, immunopathogenesis, recovery, and reinfection.
To answer the questions regarding "the potential and probability of reinfection in COVID-19 infected cases" or "the efficiency and duration of SARS-CoV-2 infection-induced immunity against reinfection" we critically evaluated the current reports on SARS-CoV-2 immunity and reinfection with special emphasis on comparative studies using animal models that generalize their finding about protection and reinfection. Also, the contribution of humoral immunity in the process of COVID-19 recovery and the role of ACE2 in virus infectivity and pathogenesis has been discussed. Furthermore, innate and cellular immunity and inflammatory responses in the disease and recovery conditions are reviewed and an overall outline of immunologic aspects of COVID-19 progression and recovery in three different stages are presented. Finally, we categorized the infected cases into four different groups based on the acquired immunity and the potential for reinfection.
In this review paper, we proposed a new strategy to predict the potential of reinfection in each identified category. This classification may help to distribute resources more meticulously to determine: who needs to be serologically tested for SARS-CoV-2 neutralizing antibodies, what percentage of the population is immune to the virus, and who needs to be vaccinated.
目前正在发生的 2019 年冠状病毒病(COVID-19)疫情仍然是一个悬而未决的问题,全球感染病例和死亡率呈上升趋势。新型冠状病毒,即严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2),针对血管紧张素转换酶 2(ACE2)受体,主要引起呼吸道疾病。尽管获得性和抗性免疫是缓解当前大流行趋势的最重要方面之一;然而,对于感染过程、免疫发病机制、恢复和再感染,我们仍然知之甚少。
为了回答有关“COVID-19 感染病例再感染的可能性和概率”或“SARS-CoV-2 感染诱导免疫对再感染的效率和持续时间”的问题,我们对当前关于 SARS-CoV-2 免疫和再感染的报告进行了批判性评估,特别强调了使用动物模型的比较研究,这些研究概括了它们关于保护和再感染的发现。此外,还讨论了体液免疫在 COVID-19 恢复过程中的作用以及 ACE2 在病毒感染性和发病机制中的作用。还回顾了疾病和恢复状态下的固有和细胞免疫以及炎症反应,并提出了 COVID-19 进展和恢复三个不同阶段免疫方面的总体概述。最后,我们根据获得的免疫和再感染的可能性,将感染病例分为四个不同的组。
在这篇综述论文中,我们提出了一种预测每个识别类别再感染潜力的新策略。这种分类方法可能有助于更精细地分配资源,以确定:谁需要进行 SARS-CoV-2 中和抗体的血清学检测,人群中有多少比例对病毒具有免疫力,以及谁需要接种疫苗。